Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts
21. Juni 2023 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
BEDFORD, Mass., June 21, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20. Juni 2023 17:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
07. Juni 2023 17:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)
05. Juni 2023 16:00 ET
|
Ultragenyx Pharmaceutical Inc.
Pediatric data show substantial induction of bone production in 1 week and a large increase in bone formation within 3 months of initiating monthly setrusumab treatment Phase 3 sites beginning to...
Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit
19. Mai 2023 08:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18. Mai 2023 17:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.
17. Mai 2023 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) has reviewed and agreed to a protocol...
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
08. Mai 2023 16:02 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx to Present at Bank of America’s 2023 Health Care Conference
05. Mai 2023 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update
04. Mai 2023 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
First quarter 2023 total revenue of $100.5 million, Crysvita® revenue of $76.0 million and Dojolvi® revenue of $14.3 million Total revenue grew 26% and Crysvita revenue grew 28% versus the first...